Paclitaxel-albumin

Phase 2Small molecule

SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Paclitaxel-albumin is one of 234 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

233

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaRecruiting

Combination TherapyRecruiting

Neoadjuvant TherapyActive, not recruiting

Efficacy and SafetyRecruiting

MetastasisNot yet recruiting

Cervical CancerRecruiting

ImmunochemotherapyRecruiting

Esophageal Squamous Cell CarcinomaPhase 2

Recruiting

Combination TherapyPhase 2

Recruiting

Neoadjuvant TherapyPhase 2

Active, not recruiting

Efficacy and SafetyPhase 2

Recruiting

MetastasisPhase 2

Not yet recruiting

Cervical CancerPhase 2

Recruiting

ImmunochemotherapyPhase 2

Recruiting

Competition

Competitive Landscape

242 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

4 2

Cytoxan

BBaxter Healthcare Corporation

Phase 3

5 3

Kineret

SSwedish Orphan Biovitrum

Phase 3

2 4

PLB1004

AAvistone Biotechnology Co., Ltd.

Phase 3

1 5

Esketamine Hydrochloride

TThe Second Hospital of Anhui Medical University

Phase 3

1 6

Cyclosporin a

Novartis

Phase 3

1 7

Efsubaglutide Alfa

SShanghai Yinnuo Pharmaceutical Technology Co., Ltd.

Phase 3

1 8

Paclitaxel-albumin

SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Phase 2

1 9

KN057

SSuzhou Alphamab Co., Ltd.

Phase 3

2 10

AD-209

AAddpharma Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Neoadjuvant Therapy

NCT04172259

Q4 2026

Phase 2Not yet recruiting

Metastasis

NCT05095467

Q4 2028

Phase 2Recruiting

Efficacy and Safety

NCT06100497

Q4 2030

Phase 2Recruiting

Immunochemotherapy

NCT06288360

Clinical

Trials by Indication[1]

Esophageal Squamous Cell Carcinoma2 trials

Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

Recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT06718205·112 enrolled

Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Unknown status·SSun Yat-sen University·Phase 2·NCT04844385·124 enrolled

Metastasis1 trial

HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction

Not yet recruiting·XXuefei.Wang·Phase 2·NCT05095467·157 enrolled

Cervical Cancer1 trial

Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer

Recruiting·TTongji Hospital·Phase 2·NCT06289751·50 enrolled

Neoadjuvant Therapy1 trial

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT04172259·156 enrolled

Esophageal Cancer1 trial

Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients

Unknown status·GGuangdong Provincial People's Hospital·Phase 2·NCT05596890·50 enrolled

7 more indications

Neoadjuvant Immunotherapy1 trial

Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC

Completed·SShanghai Zhongshan Hospital·Phase 2·NCT05807542·20 enrolled

Combination Therapy1 trial

A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients

Recruiting·SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.·Phase 2·NCT06412471·235 enrolled

Pancreatic Cancer1 trial

Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer

Terminated·ZZhejiang Provincial People's Hospital·Phase 2·NCT03585062·40 enrolled

Breast Cancer1 trial

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT06255392·200 enrolled

Esophageal Squamous Cell Cancer1 trial

Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT05322499·80 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC

Recruiting·—·Phase 2·NCT06100497·100 enrolled

Immunochemotherapy1 trial

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Recruiting·TTongji Hospital·Phase 2·NCT06288360·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Paclitaxel-albumin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Paclitaxel-albumin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Paclitaxel-albumin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Paclitaxel-albumin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q4 2028

Q4 2030

Trials by Indication[1]

Esophageal Squamous Cell Carcinoma2 trials

Metastasis1 trial

Cervical Cancer1 trial

Neoadjuvant Therapy1 trial

Esophageal Cancer1 trial

Neoadjuvant Immunotherapy1 trial

Combination Therapy1 trial

Pancreatic Cancer1 trial

Breast Cancer1 trial

Esophageal Squamous Cell Cancer1 trial

Efficacy and Safety1 trial

Immunochemotherapy1 trial

References

Drug Info

Quick Facts

Related News